Cardio Risk and Prostate Cancer

Degarelix May Reduce Risk of Cardiovascular Events in Men with Prostate Cancer

Preliminary data that suggests that men with cardiovascular disease being treated for metastatic prostate cancer may experience fewer cardiovascular events when treated with a GnRH antagonist, such as degarelix (Firmagon), compared with a GnRH agonist (Lupron, etc.).